Financial Releases
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
Panbela Provides Business Update and Reports Q2 2024 Financial Results
Panbela to Host Q2 2024 Earnings Conference Call on 8/13/24
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Panbela Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9M Gross Proceeds Priced At-the-Market
Panbela to Host Third Quarter 2023 Earnings Conference Call on 11/9/23
Panbela Provides Business Update and Reports Q2 2023 Financial Results
Panbela to Host 2nd Quarter 2023 Earnings Conference Call on 8/10/23
Panbela Provides Business Update and Reports Q1 2023 Financial Results
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
Panbela Provides Business Update and Reports Q3 2022 Financial Results
Panbela Schedules Conference Call on Nov 10, 2022 to Report 2022 Third Quarter Financial Results
November 10, 2022, 4:30 PM Eastern Time
Participant Numbers
Toll Free: 877-545-0523 / International: 973-528-0016
Participant Access Code: 598956
Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/46946
Conference Call Replay Information
Replay Number:
Toll Free: 877-481-4010 / International: 919-882-2331
Replay Passcode: 46946
Webcast Replay: https://www.webcaster4.com/Webcast/Page/2556/46946
Panbela Announces Pricing of Approximately $6 Million Public Offering
Panbela Provides Business Update and Reports Q2 2022 Financial Results
Panbela Schedules Conference Call on 8/15/22 to Report 2022 2nd Quarter Financial Results
Panbela Provides Business Update and Reports Q1 2022 Financial Results
Panbela Schedules Conference Call on May 12 to Report 2022 Q1 Financial Results
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
Panbela Schedules Conference Call on 3/24/22 to Report 2021 Fourth Quarter Financial Results
Panbela Provides Business Update and Reports Q3 2021 Financial Results
Panbela Schedules Conference Call on Nov 10 to Report Q3 2021 Financial Results
Panbela Schedules Conference Call on August 11 to Report 2021 Second Quarter Financial Results
Panbela Announces Closing of $10.0 Million Bought Deal Offering of Common Stock
Panbela Increases Previously Announced Bought Deal Offering of Common Stock to $10.0 Million
Panbela Announces $5.0 Million Bought Deal Offering of Common Stock
Panbela Set to Join Russell Microcap® Index
Panbela Provides Business Update and Reports Q1 2021 Financial Results
Panbela Schedules Conference Call on May 12, 2021 to Report 2021 First Quarter Financial Results
Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results
Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results
SBP Schedules Conference Call on Nov 12, 2020 to Report Q3 2020 Financial Results
SBP Provides Business Update and Reports Operating Results for FY2019
- Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated
- Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in treatment-naïve patients with metastatic pancreatic cancer
SBP Provides a Business Update and Reports Q3 2019 Financial Results
- Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort planned
- New U.S. sites added in anticipation of further clinical development
- Company raised $3.1 million in new capital
SBP Provides a Business Update and Files Report for Q2 2019
- Enrollment in Third Cohort of PDA Combination Study is Encouraging
- Preliminary Efficacy Signals Improve with New Data Regarding Second Cohort
- Entire $2.3 million Owed under Convertible Notes Converted to Equity
SBP Provides a Business Update and Files Report for Q1 2019
- Enrollment in Second Cohort of PDA Combination Study Completed
- New Funding Totaling $0.8 Million Secured
SBP Provides a Business Update and Files Report for Q3 2018
- Sun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with Metastatic Pancreatic Cancer
- Company announces leadership changes
- Results of new pancreatitis study presented at American Pancreatic Association meeting
SBP Provides a Business Update and Files Report for Q2 2018
- First Patients Enrolled in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- Additional Funds Raised during Q2
SBP Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update
Sun BioPharma Provides Business Update and Reports Financial Results for Q1 2016
Q3 2015 Earnings Release
Sun BioPharma Files Form 10-Q for Third Quarter 2015 and Provides Business Update